High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Current Gastroenterology Reports

Volumn 9, Issue 1, 2007, Pages 54-59

  Smith, Timothy ^b   Befeler, Alex S ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BUDESONIDE; CLADRIBINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINE; PENICILLAMINE; PENTOXIFYLLINE; PLACEBO; PREDNISONE; TACROLIMUS; URSODEOXYCHOLIC ACID;

ANOREXIA; BILE DUCT CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEATH; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MECHANISM; FLATULENCE; HUMAN; INTRAHEPATIC BILE DUCT; INTRAHEPATIC CHOLESTASIS; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; REVIEW; ULCERATIVE COLITIS;

ANIMALS; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; HUMANS; LIVER CIRRHOSIS, BILIARY; URSODEOXYCHOLIC ACID;

EID: 33947656452     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0021-z     Document Type: Review

References (48)

1. Wiesner RH, Grambsch PM, Dickson ER, et al.: Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989, 10:430-436.
2. Burak K, Angulo P, Pasha TM, et al.: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:523-526.
3. Lee Y, Kaplan MM: Primary sclerosing cholangitis. N Engl J Med 1995, 332:924-933.
4. Lindor KD, Dickson ER, Baldus WP, et al.: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994, 106:1284-1290.
5. Lindor KD, Therneau TM, Jorgensen RA, et al.: Effects of ursodeoxycholic acid on survival in patients with primary bitiary cirrhosis. Gastroenterology 1996, 110:1515-1518.
6. Poupon RE, Lindor KD, Cauch-Dudek K, et al.: Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary bitiary cirrhosis. Gastroenterology 1997, 113:884-890.
7. Angulo P, Batts KP, Therneau TM, et al.: Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999, 29:644-647.
8. Angulo P, Dickson ER, Jorgensen RA, et al.: Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999, 30:830-835.
9. Colombo C, Battezzati, Podda M, et al.: Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 1996, 23:1484-1490.
10. Benedetti A, Alvaro D, Bassotti C, et al.: Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductile fragments and isolated perfused rat liver. Hepatology 1997, 26:9-21.
11. Schmucker DL, Ohta M, Kanai S, et al.: Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 1990, 12:1216-1221.
12. Galle PR, Theilmann L, Raedsch R, et al.: Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990, 12:486-491.
13. Batta AK, Arora R, Salen G, et al.: Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J Lipid Res 1989, 30:1953-1962.
14. Colombo C, Castellani MR, Balistreri WF, et al.: Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992, 15:677-684.
15. van Milligen De Wit AWM, van Deventer SJH, Tytgat GNJ: Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995, 90:893-900.
16. Yoshikawa M, Tsujii T, Matsumura K, et al.: Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992, 16:358-364.
17. Hillaire S, Boucher E, Calmus Y, et al.: Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994, 107:781-788.
18. Van Thiel DH, Carroll P, Abu-Elmagd K, et al.: Tacrolimus (FK506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1994, 106:455-459.
19. Sterling RK, Salvatori JJ, Luketic VA, et al.: A prospective, randomizcd-controUed pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther 2004, 20:943-949.
20. Knox TA, Kaplan MM: A double-blind comrofled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994, 106:494-499.
21. Duchini A, Younossi ZM, Saven A, et al.: An open-label pilot trial of cladibrine (2-cholorodeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000, 31:292-296.
22. Kyokane K, Ichihara T, Horisawa M, et al.: Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. Hepatogastroenterology 1994, 41:449-452.
23. van Hoogstraten HJF, Vleggaar FP, Boland GJ, et al.: Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Am J Gastroenterol 2000, 95:2015-2022.
24. Angulo P, Batts KP, Jorgensen RA, et al.: Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:2333-2337.
25. Epstein MP, Kaplan MM: A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004, 49:1-4.
26. Bharucha AE, Jorgensen R, Lichtman SN, et al.: A pilot study of pentoxifyllike for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:2338-2342.
27. Lindor KD, Wiesner RH, Colwell LJ, et al.: The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991, 85:57-61.
28. Olsson RF, Broome U, Danielsson A, et al.: Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995, 108:1199-1203.
29. LaRusso NF, Wiesner RH, Ludwig J, et al.: Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988, 95:1036-1042.
30. Angulo P, Bharucha AE, Jorgensen RA, et al.: Oral nicotine in the treatment of primary sclerosing cholangitis: a pilot study. Gastroenterology 1998, 114:1204A.
31. Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, et al.: No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur J Gastroenterol Hepatol 2001, 13:171-175.
32. Farkkila M, Karvonen A, Nurmi H, et al.: Metronidazole and ursodcoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004, 40:1379-1386.
33. O'Brien CB, Senior JR, Arora-Mirchandani R, et al.: Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991, 14:838-847.
34. Beuers U, Spengler U, Kruis W, et al.: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992, 16:707-714.
35. Lo SK, Hermann R, Chapman RW, et al.: Ursodeoxycholic acid in primary sclerosing cholangitis: a double-blind placebo controlled trial. Hepatology 1992, 16:92A.
36. Stiehl A, Walker S, Stiehl L, et al.: Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis: a 3-year pilot study with a placebo-controlled study period. J Hepatol 1994, 20:57-64.
37. De Maria N, Colantoni A, Rosenbloom E, et al.: Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 1996, 43:1472-1479.
38. Lindor KD: Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997, 336:691-695.
39. van Hoogstraten HJF, Wolfhagen FHJ, van de Meeberg PC, et al.: Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998, 29:417-423.
40. Okolicsanyi L, Groppo M, Floreani A, et al.: Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of retrospective Italian multicentre survey. Dig Liver Dis 2003, 3S:325-331.
41. Angulo P, Larson DR, Therneau TM, et al.: Time course of histological progression in primary sclerosing cholangitis. Am J Gastroenterol 1999, 94:3310-3313.
42. Bansi D, Christie J, Fleming K, et al.: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind, placebo-controlled trial. Gastroenterology 1996, 110:1146A.
43. Harnois DM, Angulo P, Jorgensen RA, et al.: High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558-1562.
44. Mitchell SA, Bansi DS, Hunt N, et al.: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900-907.
45. Olsson R, Boberg KM, Schaffalitsky de Muckadell O, et al.: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464-1472.
46. Tung BY, Emond MJ, Haggitt RC, et al.: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89-95.
47. Hill MJ, Melville DM, Lennard-Jones JE, et al.: Faccal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987, 2:185-186.
48. Pardi DS, Loftus EV, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.